Home
Issues
2022
June 2022 Vol 12, No 3
April 2022 Vol 12, No 2
February 2022 Vol 12, No 1
March 2022 Vol 12 Special Feature
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
ASCO 2022 - Wrap Up
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Subscribe
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP E-Newsletters & Communications
TOP Print Edition
We will request your mailing address on the next page.
TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Issues
2022
June 2022 Vol 12, No 3
April 2022 Vol 12, No 2
February 2022 Vol 12, No 1
March 2022 Vol 12 Special Feature
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
ASCO 2022 - Wrap Up
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Featured Articles
Editorial
Adoption of Biosimilars—Why the Delay?
Read More
Original Article
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
Read More
Biosimilars
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
Read More
Original Article
Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials
Read More
Original Article
Reduced Starting Dose of Tyrosine Kinase Inhibitors in Patients with Metastatic Renal-Cell Carcinoma
Read More
Symptom Management Overview
Vancomycin Infusion Reaction: A Clinical and Therapeutic Overview
Read More
Case Reports
Managing Resistant Fusarium Infections in Immunocompromised Pediatric Patients with Malignancy: 2 Case Reports and Review of the Literature
Read More
Biosimilars
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
Read More
FDA Oncology Update
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
Read More
Tibsovo Received a New Indication, in Combination with Onureg, for Newly Diagnosed Patients with AML and IDH1 Mutation
Read More
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
Read More
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
Read More
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
Read More
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
Read More
Meeting Highlights
NCCN Guidelines Update: Initial Colorectal Screening Lowered to Age 45
Read More
New Standards of Care for Melanoma
Read More
Genetic Score Makes PSA Screening More Accurate
Read More
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
Read More
Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer
Read More
Immune Responses to COVID-19 Vaccines Low Among Patients with Hematologic Malignancies, but mRNA Vaccines Induce Strong Antibody Response in AML and MDS
Read More
A Paradigm Shift: CAR T-Cell Therapy Beats Standard of Care as Second-Line Treatment for Large B-Cell Lymphoma
Read More
Polatuzumab Vedotin plus R-CHP Outperforms R-CHOP as First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma
Read More
Ivosidenib Added to First-Line Azacitidine Improves Outcomes in Older Patients with AML
Read More
Privacy policy
Terms of Use
Home
About
Subscribe
Advertise
Contact Us
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.
